Antisense molecules: A new class of drugs

Journal of Allergy and Clinical Immunology

Volumn 137, Issue 5, 2016, Pages 1334-1346

  Potaczek, Daniel P ^a   Garn, Holger ^a   Unger, Sebastian D ^a   Renz, Harald ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

antisense; Clinical trial; DNAzyme; small interfering RNA; therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DEOXYRIBOZYME; SMALL INTERFERING RNA;

ANTISENSE THERAPY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; EYE DISEASE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; INFLAMMATORY DISEASE; METABOLIC DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; VIRUS INFECTION; EYE DISEASES; INFLAMMATION; METABOLIC DISEASES; VIRUS DISEASES;

EYE DISEASES; HUMANS; INFLAMMATION; METABOLIC DISEASES; OLIGONUCLEOTIDES, ANTISENSE; VIRUS DISEASES;

EID: 84964811379     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.12.1344     Document Type: Review

References (119)

1. L.J. Scherer, and J.J. Rossi Approaches for the sequence-specific knockdown of mRNA Nat Biotechnol 21 2003 1457 1465
2. J. Goodchild Oligonucleotide therapeutics: 25 years agrowing Curr Opin Mol Ther 6 2004 120 128
3. C.F. Bennett, and E.E. Swayze RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu Rev Pharmacol Toxicol 50 2010 259 293
4. J.C. Burnett, and J.J. Rossi RNA-based therapeutics: current progress and future prospects Chem Biol 19 2012 60 71
5. J. Winkler Oligonucleotide conjugates for therapeutic applications Ther Deliv 4 2013 791 809
6. K.E. Lundin, O. Gissberg, and C.I. Smith Oligonucleotide therapies: the past and the present Hum Gene Ther 26 2015 475 485
7. J.K. Watts, and D.R. Corey Silencing disease genes in the laboratory and the clinic J Pathol 226 2012 365 379
8. A.A. Farooqi, Z.U. Rehman, and J. Muntane Antisense therapeutics in oncology: current status Onco Targets Ther 7 2014 2035 2042
9. H.K. Karnati, R.S. Yalagala, R. Undi, S.R. Pasupuleti, and R.K. Gutti Therapeutic potential of siRNA and DNAzymes in cancer Tumour Biol 35 2014 9505 9521
10. M.L. Stephenson, and P.C. Zamecnik Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide Proc Natl Acad Sci U S A 75 1978 285 288
11. P.C. Zamecnik, and M.L. Stephenson Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide Proc Natl Acad Sci U S A 75 1978 280 284
12. J. Winkler, M. Stessl, J. Amartey, and C.R. Noe Off-target effects related to the phosphorothioate modification of nucleic acids ChemMedChem 5 2010 1344 1352
13. B.R. Yacyshyn, M.B. Bowen-Yacyshyn, L. Jewell, J.A. Tami, C.F. Bennett, D.L. Kisner, and et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease Gastroenterology 114 1998 1133 1142
14. B.R. Yacyshyn, W.Y. Chey, J. Goff, B. Salzberg, R. Baerg, A.L. Buchman, and et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease Gut 51 2002 30 36
15. B.R. Yacyshyn, A. Schievella, K.L. Sewell, and J.A. Tami Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1 Clin Exp Immunol 141 2005 141 147
16. S.J. van Deventer, J.A. Tami, and M.K. Wedel A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis Gut 53 2004 1646 1651
17. S.J. van Deventer, M.K. Wedel, B.F. Baker, S. Xia, E. Chuang, and P.B. Miner Jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis Aliment Pharmacol Ther 23 2006 1415 1425
18. P.B. Miner Jr., M.K. Wedel, S. Xia, and B.F. Baker Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: A randomized, double-blind, active-controlled trial Aliment Pharmacol Ther 23 2006 1403 1413
19. G. Monteleone, M.F. Neurath, S. Ardizzone, S.A. Di, M.C. Fantini, F. Castiglione, and et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease N Engl J Med 372 2015 1104 1113
20. G.M. Gauvreau, L.P. Boulet, D.W. Cockcroft, A. Baatjes, J. Cote, F. Deschesnes, and et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses Am J Respir Crit Care Med 177 2008 952 958
21. G.M. Gauvreau, R. Pageau, R. Seguin, D. Carballo, J. Gauthier, H. D'Anjou, and et al. Dose-response effects of TPI ASM8 in asthmatics after allergen Allergy 66 2011 1242 1248
22. H. Imaoka, H. Campbell, I. Babirad, R.M. Watson, M. Mistry, R. Sehmi, and et al. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge Clin Exp Allergy 41 2011 1740 1746
23. U. Homburg, H. Renz, W. Timmer, J.M. Hohlfeld, F. Seitz, K. Luer, and et al. Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma J Allergy Clin Immunol 136 2015 797 800
24. N. Krug, J.M. Hohlfeld, A.M. Kirsten, O. Kornmann, K.M. Beeh, D. Kappeler, and et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme N Engl J Med 372 2015 1987 1995
25. R.G. Amado, R.T. Mitsuyasu, J.D. Rosenblatt, F.K. Ngok, A. Bakker, S. Cole, and et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients Hum Gene Ther 15 2004 251 262
26. J.L. MacPherson, M.P. Boyd, A.J. Arndt, A.V. Todd, G.C. Fanning, J.A. Ely, and et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients J Gene Med 7 2005 552 564
27. R.T. Mitsuyasu, T.C. Merigan, A. Carr, J.A. Zack, M.A. Winters, C. Workman, and et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells Nat Med 15 2009 285 292
28. H.L. Janssen, H.W. Reesink, E.J. Lawitz, S. Zeuzem, M. Rodriguez-Torres, K. Patel, and et al. Treatment of HCV infection by targeting microRNA N Engl J Med 368 2013 1685 1694
29. The Vitravene Study Group A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS Am J Ophthalmol 133 2002 467 474
30. The Vitravene Study Group Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS Am J Ophthalmol 133 2002 475 483
31. The Vitravene Study Group Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS Am J Ophthalmol 133 2002 484 498
32. J. DeVincenzo, J.E. Cehelsky, R. Alvarez, S. Elbashir, J. Harborth, I. Toudjarska, and et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV) Antiviral Res 77 2008 225 231
33. J. DeVincenzo, R. Lambkin-Williams, T. Wilkinson, J. Cehelsky, S. Nochur, E. Walsh, and et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus Proc Natl Acad Sci U S A 107 2010 8800 8805
34. M.R. Zamora, M. Budev, M. Rolfe, J. Gottlieb, A. Humar, J. DeVincenzo, and et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus Am J Respir Crit Care Med 183 2011 531 538
35. R.Z. Yu, R.S. Geary, J.D. Flaim, G.C. Riley, D.L. Tribble, A.A. VanVliet, and et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe Clin Pharmacokinet 48 2009 39 50
36. J.J. Kastelein, M.K. Wedel, B.F. Baker, J. Su, J.D. Bradley, R.Z. Yu, and et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B Circulation 114 2006 1729 1735
37. F.J. Raal, R.D. Santos, D.J. Blom, A.D. Marais, M.J. Charng, W.C. Cromwell, and et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
38. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm. Accessed July 15, 2015.
39. K. Fitzgerald, M. Frank-Kamenetsky, S. Shulga-Morskaya, A. Liebow, B.R. Bettencourt, J.E. Sutherland, and et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial Lancet 383 2014 60 68
40. M.J. Graham, R.G. Lee, T.A. Bell III, W. Fu, A.E. Mullick, V.J. Alexander, and et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans Circ Res 112 2013 1479 1490
41. Q.D. Nguyen, R.A. Schachar, C.I. Nduaka, M. Sperling, A.S. Basile, K.J. Klamerus, and et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients Eye (Lond) 26 2012 1099 1105
42. Q.D. Nguyen, R.A. Schachar, C.I. Nduaka, M. Sperling, K.J. Klamerus, K. Chi-Burris, and et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study) Ophthalmology 119 2012 1867 1873
43. Q.D. Nguyen, R.A. Schachar, C.I. Nduaka, M. Sperling, A.S. Basile, K.J. Klamerus, and et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study) Invest Ophthalmol Vis Sci 53 2012 7666 7674
44. H. Kain, D. Goldblum, B. Geudelin, E. Thorin, and C. Beglinger Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: A 'first in man' phase I investigation Br J Clin Pharmacol 68 2009 169 173
45. C. Cursiefen, F. Bock, F.K. Horn, F.E. Kruse, B. Seitz, V. Borderie, and et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial Ophthalmology 116 2009 1630 1637
46. C. Cursiefen, E. Viaud, F. Bock, B. Geudelin, A. Ferry, P. Kadlecova, and et al. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study Ophthalmology 121 2014 1683 1692
47. J. Moreno-Montanes, B. Sadaba, V. Ruz, A. Gomez-Guiu, J. Zarranz, M.V. Gonzalez, and et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-adrenergic receptor 2, for lowering intraocular pressure Mol Ther 22 2014 226 232
48. S. Ormonde, C.Y. Chou, L. Goold, C. Petsoglou, R. Al-Taie, T. Sherwin, and et al. Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds J Membr Biol 245 2012 381 388
49. T. Coelho, D. Adams, A. Silva, P. Lozeron, P.N. Hawkins, T. Mant, and et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis N Engl J Med 369 2013 819 829
50. J.C. van Deutekom, A.A. Janson, I.B. Ginjaar, W.S. Frankhuizen, A. Aartsma-Rus, M. Bremmer-Bout, and et al. Local dystrophin restoration with antisense oligonucleotide PRO051 N Engl J Med 357 2007 2677 2686
51. N.M. Goemans, M. Tulinius, J.T. van den Akker, B.E. Burm, P.F. Ekhart, N. Heuvelmans, and et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy N Engl J Med 364 2011 1513 1522
52. T. Voit, H. Topaloglu, V. Straub, F. Muntoni, N. Deconinck, G. Campion, and et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): An exploratory, randomised, placebo-controlled phase 2 study Lancet Neurol 13 2014 987 996
53. V. Limmroth, F. Barkhof, N. Desem, M.P. Diamond, and G. Tachas CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS Neurology 83 2014 1780 1788
54. H.R. Buller, C. Bethune, S. Bhanot, D. Gailani, B.P. Monia, G.E. Raskob, and et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis N Engl J Med 372 2015 232 240
55. G. Monteleone, M.C. Fantini, S. Onali, F. Zorzi, G. Sancesario, S. Bernardini, and et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease Mol Ther 20 2012 870 876
56. F. Zorzi, E. Calabrese, I. Monteleone, M. Fantini, S. Onali, L. Biancone, and et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease Aliment Pharmacol Ther 36 2012 850 857
57. F. Akdim, M.E. Visser, D.L. Tribble, B.F. Baker, E.S. Stroes, R. Yu, and et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia Am J Cardiol 105 2010 1413 1419
58. F. Akdim, E.S. Stroes, E.J. Sijbrands, D.L. Tribble, M.D. Trip, J.W. Jukema, and et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J Am Coll Cardiol 55 2010 1611 1618
59. M.E. Visser, F. Akdim, D.L. Tribble, A.J. Nederveen, T.J. Kwoh, J.J. Kastelein, and et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia J Lipid Res 51 2010 1057 1062
60. F. Akdim, D.L. Tribble, J.D. Flaim, R. Yu, J. Su, R.S. Geary, and et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia Eur Heart J 32 2011 2650 2659
61. M.P. McGowan, J.C. Tardif, R. Ceska, L.J. Burgess, H. Soran, I. Gouni-Berthold, and et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS One 7 2012 e49006
62. M.E. Visser, G. Wagener, B.F. Baker, R.S. Geary, J.M. Donovan, U.H. Beuers, and et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: A randomized, double-blind, placebo-controlled trial Eur Heart J 33 2012 1142 1149
63. E.A. Stein, R. Dufour, C. Gagne, D. Gaudet, C. East, J.M. Donovan, and et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 126 2012 2283 2292
64. G.S. Thomas, W.C. Cromwell, S. Ali, W. Chin, J.D. Flaim, and M. Davidson Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: A randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 62 2013 2178 2184
65. Z. Li, M.L. Hard, J.S. Grundy, T. Singh, L.L. von Moltke, and I. Boltje Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen J Cardiovasc Pharmacol 64 2014 164 171
66. J.M. Glover, J.M. Leeds, T.G. Mant, D. Amin, D.L. Kisner, J.E. Zuckerman, and et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) J Pharmacol Exp Ther 282 1997 1173 1180
67. S. Schreiber, S. Nikolaus, H. Malchow, W. Kruis, H. Lochs, A. Raedler, and et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease Gastroenterology 120 2001 1339 1346
68. B. Yacyshyn, W.Y. Chey, M.K. Wedel, R.Z. Yu, D. Paul, and E. Chuang A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease Clin Gastroenterol Hepatol 5 2007 215 220
69. P. Miner, M. Wedel, B. Bane, and J. Bradley An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis Aliment Pharmacol Ther 19 2004 281 286
70. W.P. Maksymowych, W.D. Blackburn Jr., J.A. Tami, and W.R. Shanahan Jr. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis J Rheumatol 29 2002 447 453
71. B.D. Kahan, S. Stepkowski, M. Kilic, S.M. Katz, C.T. Van Buren, M.S. Welsh, and et al. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection Transplantation 78 2004 858 863
72. D.L. DiGiusto, A. Krishnan, L. Li, H. Li, S. Li, A. Rao, and et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma Sci Transl Med 2 2010 36ra43
73. P. Tebas, D. Stein, G. Binder-Scholl, R. Mukherjee, T. Brady, T. Rebello, and et al. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV Blood 121 2013 1524 1533
74. R. Zhang, J. Yan, H.K. Shahinian, G. Amin, Z. Lu, T. Liu, and et al. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects Clin Pharmacol Ther 58 1995 44 53
75. D. Sereni, R. Tubiana, C. Lascoux, C. Katlama, O. Taulera, A. Bourque, and et al. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects J Clin Pharmacol 39 1999 47 54
76. R.G. Gish, C. Satishchandran, M. Young, and C. Pachuk RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study Antivir Ther 16 2011 547 554
77. M. Soler, J.G. McHutchison, T.J. Kwoh, F.A. Dorr, and J.M. Pawlotsky Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment Antivir Ther 9 2004 953 968
78. J.G. McHutchison, K. Patel, P. Pockros, L. Nyberg, S. Pianko, R.Z. Yu, and et al. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients J Hepatol 44 2006 88 96
79. J.I. Henke, D. Goergen, J. Zheng, Y. Song, C.G. Schuttler, C. Fehr, and et al. microRNA-122 stimulates translation of hepatitis C virus RNA EMBO J 27 2008 3300 3310
80. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/20961-Vitravene.cfm. Accessed October 12, 2015.
81. P. Libby, P.M. Ridker, and A. Maseri Inflammation and atherosclerosis Circulation 105 2002 1135 1143
82. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
83. G.K. Hansson Immune mechanisms in atherosclerosis Arterioscler Thromb Vasc Biol 21 2001 1876 1890
84. D.P. Potaczek Links between allergy and cardiovascular or hemostatic system Int J Cardiol 170 2014 278 285
85. R. Ladeiras-Lopes, S. Agewall, A. Tawakol, B. Staels, E. Stein, R.J. Mentz, and et al. Atherosclerosis: Recent trials, new targets and future directions Int J Cardiol 192 2015 72 81
86. E.A. Stein, and F.J. Raal Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab 28 2014 309 324
87. C. Gebhard, G. Huard, E.A. Kritikou, and J.C. Tardif Apolipoprotein B antisense inhibition - update on mipomersen Curr Pharm Des 19 2013 3132 3142
88. A. Sahebkar, and G.F. Watts New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes Clin Ther 35 2013 1082 1098
89. R.D. Santos, F.J. Raal, A.L. Catapano, J.L. Witztum, E. Steinhagen-Thiessen, and S. Tsimikas Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials Arterioscler Thromb Vasc Biol 35 2015 689 699
90. A.V. Chappelow, and P.K. Kaiser Neovascular age-related macular degeneration: potential therapies Drugs 68 2008 1029 1036
91. M.R. Barakat, and P.K. Kaiser VEGF inhibitors for the treatment of neovascular age-related macular degeneration Expert Opin Investig Drugs 18 2009 637 646
92. M. Singer Advances in the management of macular degeneration F1000Prime Rep 6 2014 29
93. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
94. P.K. Kaiser, R.C. Symons, S.M. Shah, E.J. Quinlan, H. Tabandeh, D.V. Do, and et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027 Am J Ophthalmol 150 2010 33 39
95. T. Shoshani, A. Faerman, I. Mett, E. Zelin, T. Tenne, S. Gorodin, and et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis Mol Cell Biol 22 2002 2283 2293
96. A. Brafman, I. Mett, M. Shafir, H. Gottlieb, G. Damari, S. Gozlan-Kelner, and et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice Invest Ophthalmol Vis Sci 45 2004 3796 3805
97. P. Delafontaine, Y.H. Song, and Y. Li Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels Arterioscler Thromb Vasc Biol 24 2004 435 444
98. C. Miele, J.J. Rochford, N. Filippa, S. Giorgetti-Peraldi, and E. Van Obberghen Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways J Biol Chem 275 2000 21695 21702
99. C. Andrieu-Soler, M. Berdugo, M. Doat, Y. Courtois, D. BenEzra, and F. Behar-Cohen Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis Invest Ophthalmol Vis Sci 46 2005 4072 4078
100. S. Al-Mahmood, S. Colin, N. Farhat, E. Thorin, C. Steverlynck, and S. Chemtob Potent in vivo antiangiogenic effects of GS-101 (5′-TATCCGGAGGGCTCGCCATGCTGCT-3′), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1 J Pharmacol Exp Ther 329 2009 496 504
101. S. Colin, B. Darne, A. Kadi, A. Ferry, M. Favier, C. Lesaffre, and et al. The antiangiogenic insulin receptor substrate-1 antisense oligonucleotide aganirsen impairs AU-rich mRNA stability by reducing 14-3-3beta-tristetraprolin protein complex, reducing inflammation and psoriatic lesion size in patients J Pharmacol Exp Ther 349 2014 107 117
102. T.M. Miller, A. Pestronk, W. David, J. Rothstein, E. Simpson, S.H. Appel, and et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study Lancet Neurol 12 2013 435 442
103. S.A. Leachman, R.P. Hickerson, M.E. Schwartz, E.E. Bullough, S.L. Hutcherson, K.M. Boucher, and et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder Mol Ther 18 2010 442 446
104. A. Aartsma-Rus, A.A. Janson, W.E. Kaman, M. Bremmer-Bout, G.J. van Ommen, J.T. den Dunnen, and et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense Am J Hum Genet 74 2004 83 92
105. R.A. Smith, T.M. Miller, K. Yamanaka, B.P. Monia, T.P. Condon, G. Hung, and et al. Antisense oligonucleotide therapy for neurodegenerative disease J Clin Invest 116 2006 2290 2296
106. L. Winer, D. Srinivasan, S. Chun, D. Lacomis, M. Jaffa, A. Fagan, and et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy JAMA Neurol 70 2013 201 207
107. T. Brenner, Y. Hamra-Amitay, T. Evron, N. Boneva, S. Seidman, and H. Soreq The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis FASEB J 17 2003 214 222
108. Z. Argov, D. McKee, S. Agus, S. Brawer, N. Shlomowitz, O.B. Yoseph, and et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase Neurology 69 2007 699 700
109. J.D. Sussman, Z. Argov, D. McKee, E. Hazum, S. Brawer, and H. Soreq Antisense treatment for myasthenia gravis: experience with monarsen Ann N Y Acad Sci 1132 2008 283 290
110. J. Sussman, Z. Argov, Y. Wirguin, S. Apolski, V. Milic-Rasic, and H. Soreq Further developments with antisense treatment for myasthenia gravis Ann N Y Acad Sci 1275 2012 13 16
111. E. Wypasek, D.P. Potaczek, M. Alhenc-Gelas, and A. Undas PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy Thromb Res 134 2014 199 201
112. E. Wypasek, D.P. Potaczek, R. Stapor, P.J. Coucke, J. De Backer, A.M. De Paepe, and et al. First report of the genetic background of Marfan syndrome in Polish patients Pol Arch Med Wewn 123 2013 646 647
113. E. Wypasek, D.P. Potaczek, M. Alhenc-Gelas, and A. Undas Novel missense mutation C106R in the PROC gene associated with type I protein C deficiency in a young Polish man with high-risk pulmonary embolism Pol Arch Med Wewn 124 2014 75 76
114. P.H. Reitsma, H.H. Versteeg, and S. Middeldorp Mechanistic view of risk factors for venous thromboembolism Arterioscler Thromb Vasc Biol 32 2012 563 568
115. F. Roque, G. Mon, J. Belardi, A. Rodriguez, L. Grinfeld, R. Long, and et al. Safety of intracoronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty (PTCA) Antisense Nucleic Acid Drug Dev 11 2001 99 106
116. M.J. Kutryk, D.P. Foley, M. van den Brand, J.N. Hamburger, W.J. van der Giessen, P.J. deFeyter, and et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial J Am Coll Cardiol 39 2002 281 287
117. N. Kipshidze, P. Iversen, P. Overlie, T. Dunlap, B. Titus, D. Lee, and et al. First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study Cardiovasc Revasc Med 8 2007 230 235
118. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/002429/WC500136279.pdf. Accessed October 27, 2015.
119. Y.C. Zhang, M.M. Taylor, W.K. Samson, and M.I. Phillips Antisense inhibition: oligonucleotides, ribozymes, and siRNAs Methods Mol Med 106 2005 11 34